Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients

Annals of Oncology

Volumn 16, Issue 1, 2005, Pages 70-74

  Morales, L ^a   Timmerman, D ^a   Neven, P ^a   Konstantinovic, M L ^a   Carbonez, A ^b   Van Huffel, S ^c   Ameye, L ^c   Weltens, C ^a   Christiaens, M R ^a   Vergote, I ^a   Paridaens, Robert ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Katholieke Universiteit Leuven   (Belgium)

Author keywords

Aromatase inhibitors; Breast cancer; Endometrial thickness; SERM; Tamoxifen; Uterine changes

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYST; DISEASE EXACERBATION; ENDOMETRIAL DISEASE; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; HUMAN; MAJOR CLINICAL STUDY; OVARY TUMOR; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SYMPTOMATOLOGY; TRANSVAGINAL ECHOGRAPHY; UTERUS MYOMA;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; TAMOXIFEN; UTERINE DISEASES; UTERUS;

EID: 19944429637     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi021     Document Type: Article

References (27)

1. Neven P, De Muylder X, Van Belle Y et al. Tamoxifen and the uterus and endometrium. Lancet 1989; i: 375.
2. Kedar RP, Bourne TH, Powles TJ et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994; 343: 1318-1321.
3. Fisher B, Constantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
4. Neven P, Vergote I. Should tamoxifen users be screened for endometrial lesions? Lancet 1998; 351: 155-157.
5. Goldstein S. Controversy about uterine effects and safety of SERMs: the saga continues. Menopause 2002; 9: 381-384.
6. Powles TJ, Bourne T, Athanasiou S et al. The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo. Br J Cancer 1998; 78: 272-275.
7. Gardner FJE, Konje JC, Abrams KR et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000; 356: 1711-1717.
8. Rossouw J, Anderson G, Prentice R et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
9. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
10. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19: 881-894.
11. Lake D, Hudis C. Aromatase inhibitors in breast cancer: An update. Cancer Control 2002; 9: 490-498.
12. Paridaens R, Thomas J, Wildiers J et al. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anti-Cancer Drugs 1998; 9: 675-683.
13. Dowsett M, Jones A, Johnston SRD et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995; 1: 1511-1515.
14. Geisler J, King N, Dowsett M et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74: 1286-1291.
15. The ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
16. Duffy S, Jackson T. Fewer endometrial abnormalities with anastrozole than tamoxifen: Endometrial subprotocol results from the ATAC (Arimidex, Tamoxifen Alone or in Combination) early breast cancer trial in postmenopausal patients. Ann Oncol 2002; 13 (Suppl 5): 39 (Abstr 139).
17. Garrone O, Mezi S, Occelli M et al. Reversal of tamoxifen induced endometrial modifications by switching to letrozole in early breast cancer patients: A prospective TVUS study. Ann Oncol 2003; 14 (Suppl 4): iv7 (Abstr A22).
18. Lonning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of non-steroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18: 2234-2244.
19. Goss P. Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control 2002; 9: 2-8.
20. Engan T, Krane J, Johannessen DG et al. Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 1995; 36: 287-297.
21. Atalay G, Dirix L, Biganzoli L et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: A companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 2004; 15: 211-217.
22. Elisaf MS, Bairaktari ET, Nicolaides C et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001; 37: 1510-1513.
23. Dewar J, Naboltz J, Bonneterre J et al. The effect of anastrozole (Arimidex) on serum lipids-data from a randomized comparison of anastrozole versus tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 2000; 64 (Suppl 51): 51 (Abstr 164).
24. Goss P, Thomsen T, Banke-Bochita J et al. A randomized, placebo-controlled, explorative study to investigate the effect of low estrogen plasma levels on markers of bone turnover in healthy postmenopausal women during the 12-week treatment with exemestane or letrozole. Breast Cancer Res Treat 2002; 76 (Suppl 76): 576 (Abstr 267).
25. Gibson L, Gianfilippo B, Hall E et al. Transvaginal ultrasound findings in patients participating in the Intergroup Exemestane Study. Proc Am Soc Clin Oncol 2002; 21: 486 (Abstr 2005).
26. Timmerman D, Deprest J, Bourne T et al. A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. Am J Obstet Gynecol 1998; 179: 62-70.
27. Goss P, Ingle J, Martino S et al. A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1-10.